Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039696 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1PKMERO1APOLB | |
| SCHEMBL4976503 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1PKMPOLBALDH1A1 | |
| SCHEMBL4979265 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1PKMERO1APOLB | |
| SCHEMBL4456795 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1PKMPOLBALDH1A1 | |
| SCHEMBL4974926 | 0.87 | RXFP1 (0.45) | SMN1; SMN2L3MBTL1PKMPOLBALDH1A1 | |
| SCHEMBL3038462 | 0.86 | RXFP1 (0.45) | SMN1; SMN2L3MBTL1PKMERO1APOLB | |
| SCHEMBL3038427 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2L3MBTL1PKMPOLBALDH1A1 | |
| SCHEMBL4973779 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1PKMERO1APOLB | |
| SCHEMBL4976010 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1PKMERO1APOLB | |
| SCHEMBL4977021 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1PKMERO1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 4341/4885L3MBTL1 4863/4885PKM 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.